The red-hot race to develop simple infusions that reprogram immune cells to fight cancer and other diseases just got another entrant. Liberate Bio has raised $31 million in seed funding exclusively from Khosla Ventures, CEO …
Lilly says oral GLP-1 could be ‘foundational’ diabetes drug
Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.
Former FDA deputy Bumpus to lead Charles River’s new research advisory board
Namandjé Bumpus, the former FDA principal deputy commissioner, will lead a new scientific advisory board at Charles River to guide its approach to non-animal based research models that can help to reduce or replace animal …
Content evaluation of the inclusive eHealth guide: how to develop interventions for people with a lower socioeconomic position?
ObjectiveseHealth interventions favor those with higher socio-economic positions (SEPs). This can widen disparities, as people with lower SEPs may lack resources and face digital or financial barriers, making tailored solutions necessary. This study evaluates professionals’ perceptions of the Inclusive eHealth Guide (IeG) regarding its content. The aim was to ensure it meets the needs of […]
Real Chemistry, Publicis Health make moves to expand targeted marketing capabilities
In separate announcements Wednesday, a pair of agencies shared business updates both aimed at leveling up their respective abilities to connect with doctors and patients—as standard healthcare marketing practices are being upended by AI and challenged by the federal government.
Germany’s Tubulis raises €308m for ADC pipeline
Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer.
Post-Hoc Live: Are the good times in biotech … back?
The other day I went online and decided, for the first time in a while, to check the price of the $XBI. I blinked, rubbed my eyes, and blinked again. 100??? What year is it? Quietly, gradually and after months of bummer vibes, people are asking: Is biotech back? The Nasdaq biotech index is up […]
Future-proofing business capabilities with AI technologies
Artificial intelligence has always promised speed, efficiency, and new ways of solving problems. But what’s changed in the past few years is how quickly those promises are becoming reality. From oil and gas to retail, logistics to law, AI is no longer confined to pilot projects or speculative labs. It is being deployed in critical […]
Bexorg raises $23M to test drugs on ‘rebooted’ human brains from organ donors
Drugs that look promising in animals often prove ineffective in humans. That’s especially true for diseases that afflict the brain, our most complex organ, and the one that makes us most unique from rodents and …
Which big pharma had the busiest M&A team? Q3 biopharma deal analysis
Biotech execs generally point to need as the biggest driver of dealmaking. Some of the biggest players — say Merck and Bristol Myers Squibb — are losing major franchises and have a limited time to fill the …
Mark Pruzanski joins Alentis as CEO after leading Intercept and Versanis
Mark Pruzanski has found another fibrosis drug developer to lead, and this time he’s also venturing into oncology. The biotech industry veteran has joined Swiss startup Alentis Therapeutics as its new CEO, the company exclusively …
Hair loss biotech Pelage collects $120M for Phase 3 trials
In the span of three weeks, a seven-employee biotech focused on hair loss raised $120 million for Phase 3 trials that will begin next year. Los Angeles-based Pelage Pharmaceuticals announced the Series B on Wednesday …